Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial (NCT06121934) | Clinical Trial Compass
CompletedPhase 3
Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial
Bangladesh250 participantsStarted 2023-10-01
Plain-language summary
This will be a placebo-controlled, multicenter-randomized prospective study of CPLE (Carica papaya leaf extract) tabs in dengue patients (WHO-Group A, B). The study will enroll 300 eligible dengue cases into two arms: one arm receiving CPLE 1000mg t.i.d for 5 days and the other group receiving a placebo.
The main question to ask is whether CPLE reduces severe disease progression and increases platelet counts in dengue patients.
The participant will be asked to take orally available CPLE capsules at a dose of 1000 mg (2 capsules, 500mg each) or identical placebo three times a day for 5 days
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients who are confirmed dengue fever by NS1 dengue Ag or anti dengue Ab IgM positive
Exclusion Criteria:
* Children (\<18 years)
* Currently pregnant or lactating
* Patients on steroids, any immunosuppressant
* Patients who received platelet transfusion during the same admission
* Patient with other known causes of thrombocytopenia, including leukemia, ITP
* Patients with alanine aminotransferase (ALT) levels \>150 U/L
* Patient with serum creatine \>1.4 mg/dl
* S. creatine kinase (CK) \>1000 U/L
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Rise in platelet counts
Timeframe: Within five days
2
Return of hematocrit levels towards baseline
Timeframe: Within five days
Trial details
NCT IDNCT06121934
SponsorBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh